Chikungunya Virus Infection
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Bavarian NordicDenmark - Kvistgard
2 programs1
1
CHIKV VLP vaccine boosterPhase 3Vaccine1 trial
CHIKV VLP/unadjuvantedPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Bavarian NordicCHIKV VLP vaccine booster
Bavarian NordicCHIKV VLP/unadjuvanted
Clinical Trials (2)
Total enrollment: 1,245 patients across 2 trials
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
Start: Aug 2023Est. completion: Aug 2028800 patients
Phase 3Active Not Recruiting
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Start: Apr 2018Est. completion: Sep 2020445 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space